 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C24H22N4 |
| Molar mass | 366.468 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Liafensine (BMS-820836) is aserotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) which was under development byBristol-Myers Squibb for the treatment ofmajor depressive disorder.[1][2] Though it demonstrated comparable effectiveness toescitalopram andduloxetine inphase IIclinical trials, development was paused in 2013 because liafensine failed to show superior effectiveness relative to these drugs, a decision that was made likely based on its increased capacity forside effects as well aspotential for abuse.[1] Another clinical trial of liafensine began in 2022.[3]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byexpanding it. |
